(Q34283650)

English

Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy (English)

1 reference

Europe PubMed Central

1 August 2017

cholangiocarcinoma

0 references

1 reference

based on heuristic

inferred from title

author name string

H Sasaki

1

1 reference

Europe PubMed Central

1 August 2017

Y Murakami

2

1 reference

Europe PubMed Central

1 August 2017

K Uemura

3

1 reference

Europe PubMed Central

1 August 2017

T Sudo

4

1 reference

Europe PubMed Central

1 August 2017

Y Hashimoto

5

1 reference

Europe PubMed Central

1 August 2017

N Kondo

6

1 reference

Europe PubMed Central

1 August 2017

T Sueda

7

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

17 July 2014

1 reference

Europe PubMed Central

1 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

1 August 2017

111

1 reference

Europe PubMed Central

1 August 2017

7

1 reference

Europe PubMed Central

1 August 2017

1275-1284

1 reference

Europe PubMed Central

1 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.2014.399

0 references

A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

Cancer statistics, 2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

RRM1-induced metastasis suppression through PTEN-regulated pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

6 July 2018

Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.399

21 January 2018

Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.399

21 January 2018

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.399

21 January 2018

Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.399

21 January 2018

Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.399

21 January 2018

Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.399

21 January 2018

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.399

21 January 2018

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.399

21 January 2018

Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

28 October 2018

Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4183840

28 October 2018

Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25032731

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25032731

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25032731

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuva

1 reference

https://pubmed.ncbi.nlm.nih.gov/25032731

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2014.399

1 reference

Europe PubMed Central

1 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34283650&oldid=1611912349"